Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPFPX
- Development stage
- Phase 2
- Lead developer
- Forschungszentrum Jülich
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
CPFPX (8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine) is a selective radiopharmaceutical tracer used in positron emission tomography (PET) imaging. It functions as a high-affinity antagonist for the adenosine A1 receptor (A1R). The tracer is primarily used in clinical research to map and quantify the density and distribution of A1 receptors in the central nervous system. In the context of epilepsy, CPFPX PET imaging is employed to investigate alterations in the adenosinergic system, which is known to play a role in seizure termination and neuroprotection. The BRAVE study, for instance, utilizes [18F]CPFPX to assess receptor binding in patients with drug-resistant epilepsy and its relationship to respiratory control under hypercapnic conditions.
- Other names
- 8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine8-cyclopentyl-3-(3-[18F]fluoropropyl)-1-propylxanthine
02
Targets
ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)ADORA2B (Adenosine A2B receptor)ADORA3 (Adenosine A3 receptor)
Beyond the preview
Go deeper on CPFPX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPFPX.